Professor Johann de Bono was the Chief Investigator of the first phase III trial that led to this drug's approval, the AFFIRM trial, which found that enzalutamide significantly prolongs survival of men with advanced prostate cancer when used after docetaxel chemotherapy.
Subsequent studies have shown that enzalutamide also imparts major benefit when given before chemotherapy and improved overall survival, radiographic progression-free survival and time to prostate-specific antigen (PSA) progression compared with placebo across all subgroups.